What is the share price of Lyka Labs Ltd (LYKALABS) today?
The share price of LYKALABS as on 11th September 2026 is ₹82.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Lyka Labs Ltd (LYKALABS) share?
The past returns of Lyka Labs Ltd (LYKALABS) share are- Past 1 week: 5.79%
- Past 1 month: 21.82%
- Past 3 months: 20.14%
- Past 6 months: 45.41%
- Past 1 year: -17.03%
- Past 3 years: -26.60%
- Past 5 years: 4.74%
What are the peers or stocks similar to Lyka Labs Ltd (LYKALABS)?
The peers or stocks similar to Lyka Labs Ltd (LYKALABS) include:What is the market cap of Lyka Labs Ltd (LYKALABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lyka Labs Ltd (LYKALABS) is ₹266.16 Cr as of 11th September 2026.What is the 52 week high and low of Lyka Labs Ltd (LYKALABS) share?
The 52-week high of Lyka Labs Ltd (LYKALABS) is ₹101.90 and the 52-week low is ₹44.10.What is the PE and PB ratio of Lyka Labs Ltd (LYKALABS) stock?
The P/E (price-to-earnings) ratio of Lyka Labs Ltd (LYKALABS) is -26.51. The P/B (price-to-book) ratio is 2.93.Which sector does Lyka Labs Ltd (LYKALABS) belong to?
Lyka Labs Ltd (LYKALABS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Lyka Labs Ltd (LYKALABS) shares?
You can directly buy Lyka Labs Ltd (LYKALABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Lyka Labs Ltd
LYKALABS Share Price
NSE₹82.901.54% (-1.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
LYKALABS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LYKALABS Performance & Key Metrics
LYKALABS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -29.94 | 2.93 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.35 | 5.84 | 0.49% |
LYKALABS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
LYKALABS Company Profile
Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.
SUNPHARMA
PE Ratio
39.76
39.76
1Y Return
14.31%
14.31%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
86.09
86.09
1Y Return
38.56%
38.56%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.83
29.83
1Y Return
12.48%
12.48%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.17
22.17
1Y Return
7.23%
7.23%
Buy Reco %
57.69
57.69
LUPIN
PE Ratio
18.88
18.88
1Y Return
5.38%
5.38%
Buy Reco %
51.52
51.52
LYKALABS Forecast
LYKALABS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
LYKALABS
LYKALABS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
LYKALABS Income Statement
LYKALABS Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 28.08 | 30.67 | 41.18 | 34.62 | 34.25 | 33.66 | 37.75 | 31.89 | 28.64 | 42.73 | ||||||||||
Operating & Other expenses | 25.74 | 26.41 | 36.20 | 28.60 | 29.35 | 29.34 | 39.20 | 29.08 | 34.48 | 37.76 | ||||||||||
EBITDA | 2.34 | 4.26 | 4.98 | 6.02 | 4.90 | 4.32 | -1.45 | 2.81 | -5.84 | 4.97 | ||||||||||
| Depreciation/Amortization | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 | ||||||||||
| PBIT | -0.56 | 2.50 | 3.22 | 4.19 | 3.48 | 2.21 | -3.60 | 0.66 | -7.88 | 2.96 | ||||||||||
| Interest & Other Items | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.70 | 1.01 | ||||||||||
| PBT | -1.63 | 1.85 | 2.68 | 3.58 | 3.01 | 1.36 | -4.39 | -0.16 | -8.58 | 1.95 | ||||||||||
| Taxes & Other Items | 0.46 | 0.42 | 0.57 | 0.87 | 1.25 | 0.42 | -1.03 | -0.16 | -0.98 | -0.12 | ||||||||||
| Net Income | -2.09 | 1.43 | 2.11 | 2.71 | 1.76 | 0.94 | -3.36 | 0.00 | -7.60 | 2.07 | ||||||||||
| EPS | -3.83 | 0.40 | 0.58 | 0.75 | 0.49 | 0.25 | -0.94 | 0.00 | -2.10 | 0.57 |
LYKALABS Company Updates
FY 2024FY 2024
LYKALABS Stock Peers
LYKALABS Past Performance & Peer Comparison
LYKALABS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lyka Labs Ltd | -26.51 | 2.93 | — |
| Sun Pharmaceutical Industries Ltd | 39.76 | 5.44 | 0.84% |
| Torrent Pharmaceuticals Ltd | 86.09 | 10.59 | 0.69% |
| Cipla Ltd | 29.83 | 3.35 | 0.91% |
LYKALABS Stock Price Comparison
Compare LYKALABS with any stock or ETFCompare LYKALABS with any stock or ETF
LYKALABS
LYKALABS Holdings
LYKALABS Shareholdings
LYKALABS Promoter Holdings Trend
LYKALABS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LYKALABS Institutional Holdings Trend
LYKALABS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
LYKALABS Shareholding Pattern
LYKALABS Shareholding Pattern
LYKALABS Shareholding History
LYKALABS Shareholding History
Foreign Institutions
smallcases containing LYKALABS stock
smallcases containing LYKALABS stock
Looks like this stock is not in any smallcase yet.
LYKALABS Events
LYKALABS Events
LYKALABS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LYKALABS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LYKALABS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LYKALABS has not given any dividends in last 5 years
LYKALABS Dividends
LYKALABS Dividends
Hmm, looks like data is unavailable here. Please come back after some timeLYKALABS Stock News & Opinions
LYKALABS Stock News & Opinions
Articles & Videos
Earnings
Earnings
Lyka Labs Ltd consolidated sales up 50.95% on year in Q2FY2026Lyka Labs Ltd share price declined by 2% to Rs 67.62 after the company's net profit tumbled by 125.40% to Rs 2.05 crore, while revenue from operations increased sharply by 50.95% to Rs 42.31 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, easing 5.14%. It has improved by 0.74% over last one week and rose by 13.39% in last one month while the market capitalization of Lyka Labs Ltd has inched up 6.91% and 10.92% in the same period respectively. Profit before tax (PBT) of Lyka Labs Ltd stood at Rs 1.95 crore in Q2 FY26, expanding by 44.44% year-on-year, and tanking 122.70% quarter-on-quarter. EBITDA came in at Rs 4 crore, jumping 35.41% YoY and plunging by 158.42% sequentially. Total expenses posted a minor rise of 8.87% to Rs 39.77 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 11.2 crore, surging by 50.74% YoY, while employee benefits expense was at Rs 11.49 crore, falling 11% YoY. For the TTM ended FY26, revenue from operations declined slightly by 7.26% to Rs 128.44 crore, while net profit plunged by 231.65% to Rs 10.44 crore, compared to previous TTM. EBITDA soared by 1640% to Rs 7.16 crore, and PBT collapsed by 205.94% to Rs 11.78 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 5.24 crore in FY26, as against Rs 1.9 crore in FY25. Lyka Labs Ltd nosedived by 35.94% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.63% during the same period.
1 month agoCapital Market - Live
Corporate
Corporate
Lyka Labs to conduct board meetingLyka Labs will hold a meeting of the Board of Directors of the Company on 10 August 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Lyka Labs to convene AGMLyka Labs announced that the 47th Annual General Meeting(AGM) of the company will be held on 10 August 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Lyka Labs reports consolidated net loss of Rs 7.61 crore in the March 2026 quarterNet loss of Lyka Labs reported to Rs 7.61 crore in the quarter ended March 2026 as against net profit of Rs 1.77 crore during the previous quarter ended March 2025. Sales declined 16.15% to Rs 28.03 crore in the quarter ended March 2026 as against Rs 33.43 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 10.03 crore in the year ended March 2026 as against net profit of Rs 8.01 crore during the previous year ended March 2025. Sales declined 7.26% to Rs 128.44 crore in the year ended March 2026 as against Rs 138.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales28.0333.43 -16 128.44138.50 -7 OPM %-23.0112.20 --2.8512.95 - PBDT-6.544.43 PL -3.3217.89 PL PBT-8.593.02 PL -11.7811.12 PL NP-7.611.77 PL -10.038.01 PL Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Lyka Labs to announce Quarterly ResultLyka Labs will hold a meeting of the Board of Directors of the Company on 25 May 2026.
4 months agoCapital Market - Live
Corporate
Corporate
Lyka Labs to hold board meetingLyka Labs will hold a meeting of the Board of Directors of the Company on 31 March 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Lyka Labs reports consolidated nil net profit/loss in the December 2025 quarterLyka Labs reported no net profit/loss in the quarter ended December 2025 as against net profit of Rs 2.70 crore during the previous quarter ended December 2024. Sales declined 9.08% to Rs 30.73 crore in the quarter ended December 2025 as against Rs 33.80 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales30.7333.80 -9 OPM %5.3715.36 - PBDT1.995.41 -63 PBT-0.163.57 PL NP02.70 -100 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Lyka Labs to announce Quarterly ResultLyka Labs will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Lyka Labs reports consolidated net loss of Rs 3.36 crore in the September 2025 quarterNet loss of Lyka Labs reported to Rs 3.36 crore in the quarter ended September 2025 as against net profit of Rs 2.10 crore during the previous quarter ended September 2024. Sales declined 10.93% to Rs 36.66 crore in the quarter ended September 2025 as against Rs 41.16 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales36.6641.16 -11 OPM %-6.9312.03 - PBDT-2.244.44 PL PBT-4.382.67 PL NP-3.362.10 PL Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Corporate
Lyka Labs to announce Quarterly ResultLyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.48%, vs industry avg of 11.79%
Over the last 5 years, market share stayed at 0.03%